On July 23rd, 2019, the training session on WHO hepatitis C guideline was held in Tianjin, jointly hosted by China Liver Health and the Second People’s Hospital of Tianjin affiliated to Nankai University, and co-organized by the Tianjin Infectious Disease Diagnosis and Treatment Quality Control Center. More than 160 healthcare workers from over 40 hospitals in this city attended the training session.  At the training session  Guests on the rostrum Academician Zhuang Hui (honorary chairman of China Liver Health), director Liu Zhongfu from the National Center for AIDS/STD Control and Prevention under China CDC, and Dr. Chen Zhongdan from WHO representative office in China interpreted the burden, prevention and control status and challenges of hepatitis C in China and worldwide respectively. Prof. Zhu Limin from Tianjin Medical Association gave a speech on behalf of the hepatology community in Tianjin.  Academician Zhuang Hui interpreted the epidemic status and disease burden of hepatitis in mainland China.  Chairman Wei Lai presided over the training session.  Prof. Zhu Limin gave a speech. Prof. Lu Chengzhen (director of VIP clinic/hepatitis C department of Second People's Hospital of Tianjin), Prof. Li Hai (director of the department of gastroenterology/infectious disease/endoscopy of Tianjin Xiqing Hospital) and other experts gave elaborate lectures to the first-line doctors from the department of infectious disease, hepatology, gastroenterology and laboratory medicine, interpreting WHO hepatitis C guideline and discussing in depth the epidemic status of hepatitis C, antiviral treatment of special hepatitis C patients and how to easily and effectively clear hepatitis C virus. Li Mingyang, director of China Liver Health, introduced the progress of China Hepatitis C Elimination Alliance Public Welfare Project. The training session was chaired by Prof.Wei Lai, chairman of China Liver Health and director of the Hepatobiliary and Pancreatic Disease Center under Beijing Tsinghua Chang Gung Hospital, and Yan Zhongfang, dean of the Second People's Hospital of Tianjin affiliated to Nankai University.  Dean Yan Zhongfang chaired the training session. Before the training session, accompanied by director Li Mingyang and section chief Wei Hao from Xuefu street, Nankai district, Prof. Wei Lai, Dr. Chen Zhongdan, Prof. Lu Chengzhen and other experts went to the Fuhuli community and inspect the Hepatitis C Elimination Community Action in Tianjin, which was co-hosted by China Liver Health, Second People’s Hospital of Tianjin, Chinese Foundation for Hepatitis Prevention and Control and Xuefu Street. In the action, healthcare workers provided vonluntary clinical services and free hepatitis C screening, and answered residents’ questions about prevention, diagnosis and treatment, follow-up and family care of hepatitis C.  Wei Lai, Chen Zhongdan, Lu Chengzhen and other experts inspected hepatitis C screening activities in the community. Prof. Wei Lai introduced that there were about 10 million people infected with hepatitis C virus in China. According to the Global Health Sector Strategy on Viral Hepatitis (GHSS) adopted by the World Health Assembly, China should achieve the goal of 90% of HCV infections being diagnosed and 80% of confirmed cases being treated by 2030. In terms of this goal, health care workers in China still have a long way to go.  Dr. Chen Zhongdan introduced the global goal and progress of viral hepatitis elimination.  Director Liu Zhongfu introduced the epidemic status of hepatitis C in China. Prof. Wei said that Tianjin was one of the first places in China to include direct-acting antiviral agents (DAAs) into medical insurance coverage for treating hepatitis C. It had accumulated a series of experience in eliminating hepatitis C and was expected to unite efforts of local hospitals and comuunicities and to make full use of China Hepatitis C Elimination Alliance Public Welfare Project so as to further enhance hepatitis C elimination work in Tianjin and take the lead in building a Tianjin model of hepatitis C elimination in China. Prof. Lu Chengzhen positively responded to this initiative. He called on all the doctors in Tianjin to participate in creating a Tianjin model of hepatitis C elimination through joint efforts from hospitals, communicities and special high-risk groups and by improving health education, screening, testing, and treatment for hepatitis C. Specifically, first, in the diagnosis and treatment process in various departments, doctors can actively ask patients about the history and high risks of hepatitis C, promptly recommend hepatitis C screening and arrange the referral of confirmed cases. Second, in terms of health education, liver disease doctors can carry out propaganda and education on the harm, transmission routes, possibility of cure and medical insurance policy of hepatitis C in communities so as to encourage high-risk groups to receive testing, diagnosis and treatment in time. Third, provide detection and treatment services for key patients, such as hemodialysis patients, detoxification addicts and prisoners.  Prof. Lu Chengzhen interpreted the WHO hepatitis C guideline. Prof. Lu said that the new WHO hepatitis C guideline reflected the latest progress of hepatitis C treatment globally, introduced effective measures and experience of several countries in combating hepatitis C, recommended pan-genotypic drugs for hepatitis C, provided a convenient treatment plan for primary care physicians and common patients, and was worth learning for doctors in China. After Chengdu and Hebei, Tianjin was the third stop to hold the series of training sessions on WHO hepatitis C guideline under China Hepatitis C Elimination Alliance Public Welfare Project. It will vigorously promote the integration of local hepatitis C screening and management standards with international standards, improve the cure rate of hepatitis C and strengthen the management of adverse reactions in Tianjin.  Prof. Li Hai, director of the department of gastroenterology/infectious disease/endoscopy of Tianjin Xiqing Hospital, explained how to easily and efficiently clear hepatitis C virus. In March 2018, Tianjin Human Resources and Social Security Bureau issued the Notice on Determining the Capitation Payment Standard under Basic Medical Insurance for Hepatitis C Outpatient Medical Expenses and the Notice on Piloting Capitation Payment for Hepatitis C Outpatient Medical Expenses under Basic Medical Insurance. According to the notice, the pilot work of capitation payment for chronic hepatis C was officially implemented since April 1st, with the standard of 40,500 yuan per capita. People who are covered by the basic medical insurance scheme, have paid the insurance premiums for 3 years continuously in Tianjin or have a Tianjin hukou will be included in the scope of capitation payment after diagnosed with hepatitis C at the pilot hospital.  Director Li Mingyang introduced the China Hepatitis C Elimination Alliance Public Welfare Project. Li Mingyang, director of China Liver Health, introduced that the China Hepatitis C Elimination Alliance Public Welfare Project was hosted by China Liver Health and received guidance and support from WHO, Ministry of Civil Affairs, the Disease Prevention and Control Bureau under National Health Commission and China CDC. Academician Zhuang Hui served as the general counsel and Prof. Wei Lai served as the leader of the project. Since the project was launched in the Great Hall of the People in Beijing in September 2017, there has been more than 10 rounds of policy dialogue over including hepatitis C drugs into medical insurance in Shaanxi, Anhui, Jilin, Hunan, Fujian and other provinces. In addition, it has provided training for more than 2,000 grassroots liver disease doctors, carried out hepatitis C screening or supported hospitals to carry out screening for more than 22,000 people, and conducted follow-up visits for more than 1,200 patients with hepatitis C. It is expected that the general public in Tianjin will benefit from the project. |
关注官方微信 
